Illumina (NASDAQ:ILMN) CEO Francis A. Desouza sold 2,100 shares of the stock in a transaction on Monday, May 14th. The stock was sold at an average price of $268.63, for a total value of $564,123.00. Following the completion of the sale, the chief executive officer now owns 87,371 shares in the company, valued at approximately $23,470,471.73. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Illumina opened at $268.45 on Friday, according to MarketBeat Ratings. Illumina has a 12-month low of $264.12 and a 12-month high of $267.94. The company has a debt-to-equity ratio of 0.23, a quick ratio of 2.41 and a current ratio of 2.71. The firm has a market cap of $39.52 billion, a PE ratio of 55.78, a PEG ratio of 2.76 and a beta of 0.86.
Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Tuesday, April 24th. The life sciences company reported $1.45 earnings per share for the quarter, beating analysts’ consensus estimates of $1.02 by $0.43. Illumina had a return on equity of 24.93% and a net margin of 19.31%. The company had revenue of $782.00 million for the quarter, compared to the consensus estimate of $744.30 million. During the same quarter last year, the company earned $0.64 earnings per share. The firm’s revenue for the quarter was up 30.8% compared to the same quarter last year. equities analysts expect that Illumina will post 4.87 EPS for the current year.
A number of analysts have weighed in on ILMN shares. Zacks Investment Research upgraded Illumina from a “hold” rating to a “buy” rating and set a $270.00 target price on the stock in a research note on Monday, April 16th. ValuEngine upgraded Illumina from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd. BidaskClub upgraded Illumina from a “hold” rating to a “buy” rating in a research note on Saturday, March 10th. Citigroup upgraded Illumina from a “neutral” rating to a “buy” rating and increased their target price for the stock from $260.00 to $275.00 in a research note on Monday, February 5th. Finally, Canaccord Genuity reiterated a “buy” rating and issued a $265.00 target price (up previously from $255.00) on shares of Illumina in a research note on Wednesday, January 31st. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $251.14.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.